Latest Us Market News

Micro-X has secured its first supply agreement with a leading US healthcare provider for its Rover Plus mobile radiology system, opening access to over 700 facilities nationwide.

dorsaVi has acquired exclusive global rights to advanced RRAM technology, promising major performance gains in its biomedical sensors, while securing key contracts and raising $2.44 million to fuel US market growth.

Acrux Limited reports promising revenue growth driven by new topical generic launches in the US and secures crucial RDTI funding, marking a strategic shift under new CEO John Warmbrunn.

Vitrafy Life Sciences reported robust progress in Q4 FY2025, advancing its cryopreservation technology and commercial partnerships while preparing for a pivotal product launch in FY2026.

HITIQ Ltd has launched its PROTEQT smart mouthguard for grassroots sports, secured a five-year exclusive global partnership with Shock Doctor, and raised $1.9 million to fund manufacturing and market growth.

Appen Limited reported a mixed Q2 FY25 with a 6% revenue decline year-over-year, driven by a strong 77% surge in its China business that achieved profitability, while US market challenges persist. The company targets $10 million in cost savings to fuel future growth.

DroneShield Limited has reported a record-breaking second quarter with revenues surging 480% year-on-year, underpinned by a robust $176 million in committed sales and a $2.3 billion pipeline. The company is aggressively expanding manufacturing and investing in next-generation counter-drone technologies to meet soaring global demand.

Nanoveu Limited has accelerated its commercial and technological momentum with a $3.02 million capital raise, a breakthrough 33% increase in drone flight time using its edge-AI chip, and progress toward a U.S. OTCQB listing.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 alongside continued cash flow improvements.

Change Financial Limited reported a record Q4 FY25 revenue of US$4.0 million, marking a 26% year-on-year increase, alongside positive underlying EBITDA and a strong outlook for FY26.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 amid promising regulatory and market developments.

LTR Pharma has initiated commercial distribution of its nasal spray SPONTAN through Australia's Symbion pharmacy network and is advancing ROXUS development for a US launch in early 2026, while expanding its pipeline with a new intranasal treatment for swallowing disorders.